SUDARSHAN PHARMA INDUSTRIES LTD

Transaction Details

The Board of Directors of Sudarshan Pharma Industries Limited, at their meeting held on 5th September 2026, approved the acquisition of 24,23,675.64 equity shares of Common Stock of MedTherapy Biotechnology Inc., equivalent to 9.50% of the issued and outstanding share capital of the target company. The shares have a par value of US$0.0001 per share.

Additionally, Mr. Hemal Mehta (Chairman & Managing Director) and Mr. Sachin Mehta (Joint Managing Director), Promoters of the Company, will each acquire 3,82,685.63 equity shares of Common Stock of MedTherapy Biotechnology Inc., equivalent to 1.50% each of the issued and outstanding share capital of the target company.

Target Company Information

MedTherapy Biotechnology Inc. is a corporation incorporated under the laws of the State of Delaware, USA. It is described as a Boston-based global Cancer Cell & Gene Therapy Company founded in 2018 by experts from Harvard and former Novartis executives. The company operates as an end-to-end, integrated CAR-T Cell CDMO (Contract Development and Manufacturing Organization) with a commercial scale GMP manufacturing facility in New Delhi, India and a technology development site at Boston, USA.

Strategic Objectives

The acquisition objectives include:

  • Entering the U.S. market and establishing a presence there
  • Accessing the customer base, contracts, and distribution network
  • Expanding into new products and services

Regulatory Requirements

The transaction requires approval of the Reserve Bank of India under the Foreign Exchange Management Act, 1999 and Foreign Exchange Management (Overseas Investment), Rules, Regulations and Directions, 2022 as may be amended from time to time. The approval will be sought under the automatic route.

Timeline and Conditions

The indicative time period for completion of the acquisition is 31st March 2027. The relevant legal and commercial due diligence will be concluded before closure of the transaction, and all relevant FEMA regulations will be addressed.

Related Party Transaction Status

The acquisition does not fall within related party transactions, and the promoter/promoter group/group companies do not have any interest in the entity being acquired.

Board Meeting Details

The meeting of the Board of Directors commenced at 4:30 pm and concluded at 5:00 pm on 5th September 2026.

#SudarshanPharma #MedTherapy #SEBIRegulation30 #M&A #ForeignInvestment